Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Operations (2016 - 2025)

Historic Cash from Operations for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to -$23.4 million.

  • AC Immune's Cash from Operations fell 4304.98% to -$23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.7 million, marking a year-over-year decrease of 22233.76%. This contributed to the annual value of $75.2 million for FY2024, which is 20960.5% up from last year.
  • As of Q3 2025, AC Immune's Cash from Operations stood at -$23.4 million, which was down 4304.98% from -$19.6 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Cash from Operations registered a high of $80.8 million during Q2 2024, and its lowest value of -$25.1 million during Q1 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$18.1 million (2022), whereas its average is -$11.0 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 61175.6% in 2024, then plummeted by 193526.55% in 2025.
  • AC Immune's Cash from Operations (Quarter) stood at -$19.3 million in 2021, then rose by 6.55% to -$18.1 million in 2022, then decreased by 2.14% to -$18.5 million in 2023, then skyrocketed by 136.7% to $6.8 million in 2024, then plummeted by 444.73% to -$23.4 million in 2025.
  • Its Cash from Operations stands at -$23.4 million for Q3 2025, versus -$19.6 million for Q2 2025 and -$21.5 million for Q1 2025.